Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M. Tomita Y, et al. Among authors: sugiyama y. Jpn J Clin Oncol. 2021 Dec 1;51(12):1770. doi: 10.1093/jjco/hyab161. Jpn J Clin Oncol. 2021. PMID: 34585728 Free PMC article. No abstract available.
Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kabu K, Tajima Y, Oya M. Tomita Y, et al. Among authors: sugiyama y. Jpn J Clin Oncol. 2021 May 28;51(6):966-975. doi: 10.1093/jjco/hyaa266. Jpn J Clin Oncol. 2021. PMID: 33594427 Free PMC article.
Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M. Tomita Y, et al. Among authors: sugiyama y. Jpn J Clin Oncol. 2021 Nov 1;51(11):1656-1664. doi: 10.1093/jjco/hyab114. Jpn J Clin Oncol. 2021. PMID: 34350454 Free PMC article.
CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.
Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M. Motoshima T, et al. Among authors: sugiyama y. Oncol Lett. 2016 Mar;11(3):1911-1916. doi: 10.3892/ol.2016.4132. Epub 2016 Jan 20. Oncol Lett. 2016. PMID: 26998099 Free PMC article.
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A; PROSTAT-BSI Investigators. Nakajima K, et al. Among authors: sugiyama y. Int J Urol. 2021 Sep;28(9):955-963. doi: 10.1111/iju.14614. Epub 2021 Jun 19. Int J Urol. 2021. PMID: 34148264 Free PMC article.
Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators. Koshiro N, et al. Among authors: sugiyama y. Int J Urol. 2022 Dec;29(12):1477-1487. doi: 10.1111/iju.15022. Epub 2022 Sep 7. Int J Urol. 2022. PMID: 36070138
Clear cell carcinoma of the seminal vesicle in a young adult.
Murakami H, Motoshima T, Kurahashi R, Murakami Y, Sugiyama Y, Yamaguchi T, Yatsuda J, Asato T, Mikami Y, Kamba T. Murakami H, et al. Among authors: sugiyama y. IJU Case Rep. 2022 Jul 13;5(5):406-409. doi: 10.1002/iju5.12502. eCollection 2022 Sep. IJU Case Rep. 2022. PMID: 36090927 Free PMC article.
2,679 results